Patients with COVID-19 requiring treatment with CRRT
Conditions
Interventions
Observation group:nafamostat mesylate combined with regional citrate anticoagulation
Control group:regional citrate anticoagulation
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The diagnosis is consistent with COVID-19 infection (critical type); Age >= 18 years old; CRRT treatment is necessary for the condition; The estimated duration of CRRT treatment is longer than 24 hours; Informed consent of the patient.
Exclusion criteria
Exclusion criteria: A history of allergy to sodium citrate or nafamostat mesylate; Other systemic anticoagulants were used within 24h before or during CRRT treatment; There is active bleeding; Lactic acid level > 4mmol/L; Pregnant patients; Organ transplant patients; Severe coagulopathy (ISTH score >= 5, International Association for Thrombosis and Hemostasis standards).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Life of extracorporeal circulation line;All-cause mortality at 14, 28 and 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative treatment time of CRRT;Mechanical ventilation time;Length of stay;activated clotting time of whole blood;hemoglobin;platelets;Prothrombin time;Activated partial thromboplastin time;Interleukin-6;procalcitonin; | — |
Countries
China
Contacts
Public ContactZhang Ling
West China Hospital, Sichuan University
Outcome results
None listed